{"id":110173,"date":"2026-04-15T09:38:36","date_gmt":"2026-04-15T07:38:36","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/irb-barcelona-identifies-a-key-biomarker-for-predicting-response-to-immunotherapy-in-patients-with-colon-and-rectal-cancer\/"},"modified":"2026-04-15T09:38:36","modified_gmt":"2026-04-15T07:38:36","slug":"irb-barcelona-identifies-a-key-biomarker-for-predicting-response-to-immunotherapy-in-patients-with-colon-and-rectal-cancer","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/irb-barcelona-identifies-a-key-biomarker-for-predicting-response-to-immunotherapy-in-patients-with-colon-and-rectal-cancer\/","title":{"rendered":"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer"},"content":{"rendered":"

A new study, led by the Hospital del Mar Research Institute (HMRIB) and the Institut de Recerca Biom\u00e8dica de Barcelona (IRB Barcelona<\/a>), based at the Parc Cient\u00edfic de la Universitat de Barcelona (PCB-UB), together with the CIBER Oncology Area (CIBERONC), indicates that determining the levels of the protein CTHRC1 can be used to establish the prognosis of the response to immunotherapy in patients with colon and rectal cancer, while also opening up new avenues for tackling this type of tumour. The research, published in the journal Gut, shows that this biomarker can be detected using the diagnostic tests routinely employed in the clinical practice of any Pathology department.<\/strong><\/p>\n

Determining the presence of a protein in non-tumour cells within the cancer microenvironment could be one of the keys to establishing prognosis in patients with colon and rectal cancer. It may also help identify which patients could benefit from immunotherapy or from treatments aimed at inhibiting a specific protein linked to tumour proliferation. These specific cells, which express a particular protein (CTHRC1) and are known as CTHRC1(+) CAFs, belong to a population of cancer-associated fibroblasts\u2014connective tissue cells that, in tumours, form part of their microenvironment and help them proliferate.<\/p>\n

To determine their potential role as a biomarker, using immunohistochemistry tests routinely applied in Pathology services for colon and rectal tumours, the researchers carried out a complex multidisciplinary validation process.<\/p>\n

First, the potential of CTHRC1(+) CAFs as predictive markers of treatment response was studied across 17 cohorts comprising samples from nearly 3,000 patients. Next, tumour cell RNA was analysed at the single-cell level to identify the most promising cell populations. Finally, the proteins they expressed were determined. At the end of the process, only those cells expressing a specific protein\u2014CTHRC1(+) CAFs\u2014retained predictive capacity.<\/p>\n

The results were validated using patient samples from individuals who had received different treatments across several national and international hospitals, including the Hospital Cl\u00ednico Universitario de Valencia, the Hospital Universitario Germans Trias i Pujol, and the Hospital del Mar. In this regard, Dr. Alexandre Calon<\/strong>, one of the study\u2019s principal investigators and coordinator of the Translational Research Group in Tumour Microenvironment at the Hospital del Mar Research Institute, highlights that \u201cthe validated marker maintains strong predictive and prognostic performance across patient cohorts.\u201d<\/p>\n

Another key finding is that it may also help determine patient prognosis. The new marker enables measurement of the activity of a cytokine in the tumour microenvironment, TGF-beta, which is associated with poorer disease outcomes. High levels of CTHRC1 protein are linked to treatment resistance. This also suggests a potential therapeutic target in the form of inhibitors of this protein, which should be further investigated. \u201cThe tumour microenvironment plays a decisive role in the progression of colorectal cancer and in its response to treatments. Over the years, our research has shown that TGF-beta is a key regulator of this ecosystem, modulating the behaviour of stromal cells surrounding the tumour. The identification of CTHRC1 as a TGF-beta-induced factor exemplifies how basic research can lead to clinically applicable biomarkers,\u201d states Dr. Eduard Batlle<\/strong>, ICREA researcher at IRB Barcelona and member of CIBERONC.<\/p>\n

Determining which patients may benefit from immunotherapy<\/strong><\/h3>\n

In this same context, the findings may also help advance the use of immunotherapy in patients with colon and rectal cancer. Currently, this approach is applicable to only a very small proportion of patients\u2014around 5%\u2014and it is not effective in all cases. The study indicates that the presence of CTHRC1(+) CAFs makes it possible to determine the state of immune cells within the tumour and their ability to act against neoplastic cells. Moreover, its usefulness is not limited to patients previously considered eligible for this treatment.<\/p>\n

\u201cThis biomarker improves the selection of patients who could potentially benefit from immunotherapy,\u201d explains Dr. Clara Montagut<\/strong>, also involved in the study and Head of Section of the Medical Oncology Department at Hospital del Mar and researcher at its institute. This, she notes, \u201ccould help guide therapeutic strategies for patients with colon and rectal cancer.\u201d Furthermore, the results could be applicable to other tumour types, such as breast and lung cancer.<\/p>\n

One of the major innovations of the study is that the presence of the validated marker can be determined using immunohistochemistry tests, which are routinely available in any hospital Pathology service. Dr. Mar Iglesias<\/strong>, first author of the study, researcher at HMRIB and CIBERONC, and Head of the Pathology Department at Hospital del Mar (part of the dibi network), explains that \u201cthe results position CTHRC1(+) CAFs as a useful marker with the potential to be integrated into routine clinical practice in our services and hospitals, thereby helping to guide the selection of the most appropriate treatment for each patient.\u201d<\/p>\n

This study has been made possible thanks to the support of various organizations, including the Spanish Association Against Cancer (AECC).<\/p>\n

\u00bb Reference article: <\/strong>Mar Iglesias Coma, Jordi Badia-Ramentol, Carolina Martinez-Ciarpaglini, Jenniffer Linares, Noelia Tarazona, Nuria Mulet-Margalef, Paula Tornero Pi\u00f1ero, Anna Sallent-Aragay, Alba Recort-Bascuas, Joan Gibert, Marta Sant-Albors, Daniele V.F. Tauriello, Melba Cruz-Moral, Marina Carreras-Gallardo, Elena Sancho, Clara Morral Martinez, Marta Garrido, Jos\u00e9 Luis Manzano Mozo, Andr\u00e9s Cervantes, Clara Montagut, Eduard Batlle, Alexandre Calon. A Stromal Biomarker\u2013Based Framework for Identifying pMMR\/MSS and dMMR\/MSI Colorectal Cancers With Poor Outcomes and Limited Benefit from Immunotherapy. GUT (2026). \u00a0DOI:\u00a0https:\/\/dx.doi.org\/10.1136\/gutjnl-2025-336804<\/a><\/p>\n

\u00bb Link to the news: <\/strong>IRB Barcelona website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A new study, led by the Hospital del Mar Research Institute (HMRIB) and the Institut de Recerca Biom\u00e8dica de Barcelona (IRB Barcelona), based at the Parc Cient\u00edfic de la Universitat…<\/p>\n","protected":false},"author":14,"featured_media":110164,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[260],"class_list":["post-110173","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-irb-en"],"acf":[],"yoast_head":"\nIRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"A new study, led by the Hospital del Mar Research Institute (HMRIB) and the Institut de Recerca Biom\u00e8dica de Barcelona (IRB Barcelona), based at the Parc Cient\u00edfic de la Universitat...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T07:38:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer\",\"datePublished\":\"2026-04-15T07:38:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/\"},\"wordCount\":911,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg\",\"keywords\":[\"IRB\"],\"articleSection\":[\"SCIENCE\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/\",\"name\":\"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg\",\"datePublished\":\"2026-04-15T07:38:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/","og_locale":"en_US","og_type":"article","og_title":"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer - Parc Cient\u00edfic de Barcelona","og_description":"A new study, led by the Hospital del Mar Research Institute (HMRIB) and the Institut de Recerca Biom\u00e8dica de Barcelona (IRB Barcelona), based at the Parc Cient\u00edfic de la Universitat...","og_url":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-04-15T07:38:36+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer","datePublished":"2026-04-15T07:38:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/"},"wordCount":911,"image":{"@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg","keywords":["IRB"],"articleSection":["SCIENCE"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/","url":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/","name":"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg","datePublished":"2026-04-15T07:38:36+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/2023-05-12-IRB-EDUARD-BATLLE-79341_0-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/lirb-barcelona-identifica-un-biomarcador-clau-per-al-pronostic-de-la-immunoterapia-en-pacients-amb-cancer-de-colon-i-recte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"IRB Barcelona identifies a key biomarker for predicting response to immunotherapy in patients with colon and rectal cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=110173"}],"version-history":[{"count":0,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110173\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/110164"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=110173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=110173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=110173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}